1. Reconciled Neurology, Psychiatry, and Pain Execution & Stop-Cause Profile
| Clinical Trial Metric | Verified Value | Operational Context |
|---|---|---|
| Total Phase II & III Protocols (2018 to 2026) | 4,809 | Deterministic primary MeSH and condition-keyword assignment |
| Active Concurrent Pipeline | 1,909 | Recruiting, enrolling by invitation, and active follow-up protocols |
| Completed vs Prematurely Stopped | 1,763 / 628 | 26.27% closed-trial attrition ratio across 2,391 closed protocols |
| Slow Accrual vs Safety & Futility Stops | 137 / 68 / 54 | Slow accrual (WS1) vs clinical safety (WS4) vs interim futility (WS5) |
| Physical Hospital Site Disclosure Rate | 86.4% | Named hospital campus participations vs anonymized CRO site slots |
2. Leading Consolidated Trial Sponsors Focused on Neurology, Psychiatry, and Pain
| Sponsor Hub | Sector | Protocols | Active | Completed | FDA NDA/BLA |
|---|---|---|---|---|---|
| VA Office of Research and Development | Federal / Public Agency | 112 | 59 | 34 | 0 |
| Brigham and Women's Hospital | Academic / Institutional Sponsor | 106 | 49 | 36 | 0 |
| Beijing Tiantan Hospital | Academic / Institutional Sponsor | 86 | 41 | 22 | 0 |
| Medical University of South Carolina | Academic / Institutional Sponsor | 74 | 33 | 31 | 0 |
| Chang Gung Memorial Hospital | Academic / Institutional Sponsor | 70 | 28 | 12 | 0 |
| University of Calgary | Academic / Institutional Sponsor | 65 | 33 | 6 | 0 |
| Biogen | Biopharma Industry | 61 | 22 | 19 | 12 |
| Otsuka Pharmaceutical Development & Commercialization | Biopharma Industry | 58 | 16 | 33 | 0 |
| Kafrelsheikh University | Academic / Institutional Sponsor | 51 | 11 | 17 | 0 |
| Capital Medical University | Academic / Institutional Sponsor | 47 | 18 | 10 | 0 |
| Neurocrine Biosciences | Biopharma Industry | 46 | 19 | 17 | 4 |
| University of British Columbia | Academic / Institutional Sponsor | 42 | 14 | 6 | 0 |
3. Representative Multi-Center Phase II & III Neurology, Psychiatry, and Pain Studies
| NCT Study | Protocol Brief Title | Sponsor | Phase | Status |
|---|---|---|---|---|
| NCT07325292 | Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | Sanofi | Phase III | RECRUITING |
| NCT04302870 | Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial | University of Edinburgh | Phase II/III | RECRUITING |
| NCT06290141 | A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Sanofi | Phase III | RECRUITING |
| NCT04965675 | A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | H. Lundbeck | Phase III | RECRUITING |
| NCT07174310 | A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | Roche / Genentech | Phase III | RECRUITING |
| NCT04867317 | Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) | VA Office of Research and Development | Phase III | RECRUITING |
| NCT07687706 | Tegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke) | Hanyang University Guri Hospital | Phase III | RECRUITING |
| NCT07430956 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable | Regeneron Pharmaceuticals | Phase III | RECRUITING |
| NCT07792681 | Efficacy and Safety of BR005-036C Tablets for the Acute Treatment of Migraine in Adults | Brise Pharmaceuticals Co | Phase II/III | RECRUITING |
| NCT07218354 | Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE) | VA Office of Research and Development | Phase III | RECRUITING |
| NCT06157502 | Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY) | Beijing Tiantan Hospital | Phase III | RECRUITING |
| NCT06315231 | Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients | Simcere Pharmaceutical Co | Phase II | RECRUITING |
| NCT07721961 | A Study of MI078 for Postpartum Depression | Nanjing Minova Pharmaceutical Co | Phase III | RECRUITING |
| NCT07777861 | A Phase II Trial of G01 Eye Drops for Glaucomatous Optic Neuropathy | Qingdao WanMing BioCell Pharmaceutics Co | Phase II | RECRUITING |
| NCT07262645 | Near-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A) | Danyang Huichuang Medical Equipment Co | Phase III | RECRUITING |
| NCT07219953 | A Study of Brenipatide in Participants With Alcohol Use Disorder | Eli Lilly and Company | Phase III | RECRUITING |
Related Therapeutic Condition Hubs & Crosswalks
Compare adjacent clinical cohorts: Oncology and Hematology · Rare Genetic, Women's Health, and Other · Infectious Disease and Vaccines · Immunology, Rheumatology, and Dermatology, browse the interactive Hospital & Sponsor Directory, or read the Healthcare Price & Patent Cliff Crosswalk.